Aprazer – Pharmaceutical Manufacturer
Aprazer
Aprazer Healthcare Pvt. Ltd. is an Indian pharmaceutical company founded in 2017, with its office in New Delhi. Aprazer makes and exports generic medicines.
Its key areas are oncology, hepatology (hepatitis B and C) and HIV. The range also covers gastroenterology, nephrology, rheumatology, critical care and urology. The company produces tablets and capsules, injectables including pre-filled syringes, and lyophilised products.
According to the company, its products are made at six manufacturing units to WHO-GMP standards and exported to more than 20 countries in South-East Asia, Africa and South America. Aprazer also offers contract manufacturing.
Aprazer's oncology portfolio consists of generics of modern targeted drugs — tyrosine kinase inhibitors, a PARP inhibitor and a CDK4/6 inhibitor — as well as hormonal treatments for prostate cancer.
Unifarm carries Aprazer's medicines: Olabir (olaparib), Palbocib (palbociclib), Lenvakast (lenvatinib), Sorafekast (sorafenib), Sutekast (sunitinib), Pazokast 400 (pazopanib), Inlybest (axitinib), Abirakast (abiraterone acetate), Indenza (enzalutamide), Velakast (sofosbuvir/velpatasvir), Sofokast-Plus (sofosbuvir/daclatasvir), Tafsure (tenofovir alafenamide) and more — see the full list below.